Circulating natural killer cells and their association with breast cancer and its clinico-pathological characteristics

Purpose: Natural killer (NK) cells play a critical role in cancer immunosurveillance and hold promise as both therapies and prognostic markers in advanced disease. We explore factors that may influence NK cell concentration in the peripheral blood of women with breast cancer in Côte d’Ivoire compared to healthy controls and implications for future research in our context. Methods: In this cross-sectional case-control study, blood samples were taken from 30 women diagnosed with breast cancer within 6 months of diagnosis and fifteen healthy women at University Teaching Hospital [Centre Hospitalier Universitaire (CHU)] Treichville in Abidjan, Côte d’Ivoire, from March to September 2018. The blood draw could take place at any time following diagnosis and through treatment. Demographic and clinical data were collected. NK cells were isolated, stained, analysed and counted using the flow cytometer at the Department of Immunology at CHU of Cocody. All p -values were two-sided. Results: Mean age among 30 women with breast cancer was 49 years old compared to 45 years old for 15 controls ( p = 0.41). Among 30 women with breast cancer, 4 (13.3%) had Stage 2 disease, 14 (46.7 %) at Stage 3, and 12 (40%) at Stage 4. Fourteen (46.7%) had breast cancer that was hormone receptor-positive (HR+) HER2-negative, 10 (33.3%) had triple-negative cancer, three (10.0%) had HR+HER2+ disease, and three (10.0%) HR-HER2+ cancer. NK cell concentration was not associated with cancer diagnosis, age, cancer stage, subtype, or type of treatment patients received ( p > 0.05). Conclusion: Although we did not find an association between NK cell concentration, cancer characteristics or treatment, our results be limited by the small sample size and timing of blood draw. Our next steps include a larger study to explore circulating NK cells prior to any treatment and NK cell infiltration within breast cancer tumour and correlating this with response to treatment and prognosis.

[1]  W. Y. van der Plas,et al.  The increased need for palliative cancer care in Sub-Saharan Africa. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  M. Barda-Saad,et al.  Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy? , 2020, Frontiers in Immunology.

[3]  Hua Wang,et al.  NK Cell-Based Immune Checkpoint Inhibition , 2020, Frontiers in Immunology.

[4]  P. Rockers,et al.  Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of Access Accelerated. , 2020, Public health.

[5]  William T. E. Pitkeathly,et al.  Genetic diversity affects the nanoscale membrane organization and signaling of natural killer cell receptors , 2019, Science Signaling.

[6]  K. Wagner,et al.  Regulation and New Treatment Strategies in Breast Cancer. , 2019, Journal of life sciences.

[7]  K. Leandersson,et al.  Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer , 2019, Scientific Reports.

[8]  A. Witkowska,et al.  KIR specificity and avidity of standard and unusual C1, C2, Bw4, Bw6 and A3/11 amino acid motifs at entire HLA:KIR interface between NK and target cells, the functional and evolutionary classification of HLA class I molecules , 2019, International journal of immunogenetics.

[9]  S. Combs,et al.  Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy – potential markers for predicting breast cancer recurrence? , 2019, Radiation oncology.

[10]  J. Boudreau,et al.  Novel Approach to Cell Surface Discrimination Between KIR2DL1 Subtypes and KIR2DS1 Identifies Hierarchies in NK Repertoire, Education, and Tolerance , 2019, Front. Immunol..

[11]  É. Vivier,et al.  Targeting natural killer cells in solid tumors , 2019, Cellular & Molecular Immunology.

[12]  F. Wambalaba,et al.  Prevalence and Capacity of Cancer Diagnostics and Treatment: A Demand and Supply Survey of Health-Care Facilities in Kenya , 2019, Cancer control : journal of the Moffitt Cancer Center.

[13]  A. Jemal,et al.  Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort study of 573 women. , 2018, Breast.

[14]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[15]  S. Rutella,et al.  Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer , 2018, Front. Immunol..

[16]  B. J. Abdullah,et al.  Effect of Aging on NK Cell Population and Their Proliferation at Ex Vivo Culture Condition , 2018, Analytical cellular pathology.

[17]  L. Jones,et al.  Mechanisms of immune evasion in breast cancer , 2018, BMC Cancer.

[18]  L. Jones,et al.  Mechanisms of immune evasion in breast cancer , 2018, BMC Cancer.

[19]  C. Espina,et al.  Delayed presentation and diagnosis of breast cancer in African women: a systematic review , 2017, Annals of epidemiology.

[20]  N. Keating,et al.  Quality of Breast Cancer Treatment at a Rural Cancer Center in Rwanda , 2017, Journal of global oncology.

[21]  Ernest Osei Bonsu,et al.  Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer , 2016, Annals of Surgical Oncology.

[22]  L. Shulman,et al.  Breast Cancer in Sub-Saharan Africa: Challenges and Opportunities to Reduce Mortality. , 2016, The oncologist.

[23]  K. Horgan,et al.  Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer , 2016, Breast Cancer Research.

[24]  B. Suarez-Alvarez,et al.  Secretory pathways generating immunosuppressive NKG2D ligands , 2014, Oncoimmunology.

[25]  S. Olatoke,et al.  Socio-demographic and clinical profile of immuno-histochemically confirmed breast cancer in a resource limited country , 2014, The Pan African medical journal.

[26]  L. Brinton,et al.  Breast cancer in Sub-Saharan Africa: opportunities for prevention , 2014, Breast Cancer Research and Treatment.

[27]  M. Touré,et al.  Facteurs liés au diagnostic tardif des cancers du sein en Afrique-sub-saharienne : cas de la Côte d’Ivoire , 2013 .

[28]  F. Marincola,et al.  Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients , 2013, Journal of Translational Medicine.

[29]  J. Ferlay,et al.  Global estimates of cancer prevalence for 27 sites in the adult population in 2008 , 2013, International journal of cancer.

[30]  F. Bertucci,et al.  Peripheral Blood NK Cells from Breast Cancer Patients Are Tumor-Induced Composite Subsets , 2013, The Journal of Immunology.

[31]  T. Cotechini,et al.  Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. , 2011, Cancer research.

[32]  R. Talamini,et al.  A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies , 2011, Breast Cancer Research.

[33]  Stephanie Alexander,et al.  Cancer Invasion and the Microenvironment: Plasticity and Reciprocity , 2011, Cell.

[34]  F. Bertucci,et al.  Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. , 2011, The Journal of clinical investigation.

[35]  A. Pera,et al.  Immunosenescence of Human Natural Killer Cells , 2011, Journal of Innate Immunity.

[36]  J. M. de Andrade,et al.  Lymphocyte Subpopulations in Patients with Advanced Breast Cancer Submitted to Neoadjuvant Chemotherapy , 2000, Tumori.

[37]  C. Der,et al.  Increasing Complexity of the Ras Signaling Pathway* , 1998, The Journal of Biological Chemistry.

[38]  A. Rezaei,et al.  Optimization of In Vitro Expansion and Activation of Human Natural Killer Cells against Breast Cancer Cell Line , 2020, Avicenna journal of medical biotechnology.

[39]  K. Arihiro,et al.  Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[40]  O. Adedeji.  Cancer in Sub-Saharan Africa , 2017 .

[41]  O. Ginsburg,et al.  Global Health Initiatives of the International Oncology Community. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[42]  M. Duma,et al.  Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  W. Murphy,et al.  Advantages and clinical applications of natural killer cells in cancer immunotherapy , 2013, Cancer Immunology, Immunotherapy.

[44]  J. Russo,et al.  Relationship of natural killer cytotoxicity to clinical and biochemical parameters of primary human breast cancer , 2005, Breast Cancer Research and Treatment.

[45]  F. Bonilla,et al.  Natural killer activity in patients with breast cancer. , 1990, European journal of gynaecological oncology.